Gelley F, Zadori G, Firneisz G, Wagner L, Fehervári I, Gerlei Z, Fazakas J, Papai S, Lengyel G, Sarvary E, Nemes B
Departure of Transplantation and Surgery, Semmelweis University Budapest, Hungary.
Transplant Proc. 2011 May;43(4):1281-2. doi: 10.1016/j.transproceed.2011.03.065.
De novo diabetes mellitus is a common complication after liver transplantation. It is strongly associated with hepatitis C virus (HCV) infection. We analyzed the relationship between HCV recurrence and de novo diabetes among the Hungarian liver transplant population. This retrospective study included cases from 1995 to 2009 on 310 whole liver transplantations. De novo diabetes was defined if the patient had a fasting plasma glucose ≥126 mg/dL permanently after the third month post liver transplantation, and/or required sustained antidiabetic therapy. De novo diabetes occured in 63 patients (20%). The cumulative patient survival rates at 1, 3, 5, and 8 years were 95%, 91%, 88%, and 88% in the control group, and 87%, 79%, 79%, and 64% in the de novo group, respectively (P=.011). The majority of the patients in the de novo group were HCV positive (66% vs 23%). Early virus recurrence within 5 months was associated with the development of diabetes (80% vs 20% non-diabetic controls; P=.017). The fibrosis (2.05 ± 1.5 vs 1 ± 1; P=.039) and Knodell scores (3.25 ± 2 vs 1.69 ± 1.2; P=.019) were higher among the de novo group after antiviral therapy. Rapid recurrence, more severe viremia, and fibrosis showed significant roles in the developement of de novo diabetes after liver transplantation.
新发糖尿病是肝移植后常见的并发症。它与丙型肝炎病毒(HCV)感染密切相关。我们分析了匈牙利肝移植人群中HCV复发与新发糖尿病之间的关系。这项回顾性研究纳入了1995年至2009年期间310例全肝移植病例。如果患者在肝移植后第三个月后空腹血糖持续≥126mg/dL,和/或需要持续的抗糖尿病治疗,则定义为新发糖尿病。63例患者(20%)发生了新发糖尿病。对照组1年、3年、5年和8年的累积患者生存率分别为95%、91%、88%和88%,新发糖尿病组分别为87%、79%、79%和64%(P=0.011)。新发糖尿病组的大多数患者HCV呈阳性(66%对23%)。5个月内的早期病毒复发与糖尿病的发生有关(糖尿病患者80%,非糖尿病对照组20%;P=0.017)。抗病毒治疗后,新发糖尿病组的纤维化程度(2.05±1.5对1±1;P=0.039)和Knodell评分(3.25±2对1.69±1.2;P=0.019)更高。快速复发、更严重的病毒血症和纤维化在肝移植后新发糖尿病的发生中起重要作用。